Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.41 USD
+0.26 (5.05%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CAPR 5.41 +0.26(5.05%)
Will CAPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CAPR
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
Other News for CAPR
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics announces Type B meeting with FDA for CAP-1002 program